About us | Advertise with us | Contact us


Posted: 20 November 2025 | Drug Target Review | No comments yet
A new CAR-T treatment developed in Switzerland has shown striking early success against glioblastoma, one of the deadliest brain cancers, and is now moving towards human trials.
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospital (HUG) have developed a new form of CAR-T cell therapy capable of destroying glioblastoma cells. The researchers reported a breakthrough in an animal model that could now lead to human clinical trials, helping to fight one of the deadliest forms of brain cancer with five-year survival rate of less than 5 percent. 
Glioblastoma typically forms as a mass in the brain composed of tumour cells and various supporting cells. Unlike other cancers that respond to immunotherapy, such as melanoma or some lung cancers, glioblastoma contains very few T cells – the immune system’s main cancer-fighting cells.
Glioblastoma typically forms as a mass in the brain composed of tumour cells and various supporting cells.
‘‘However, glioblastoma is unique in that it contains very few T cells, the immune cells that are able to recognise cancer cells and destroy them,’’ explains Valérie Dutoit of the UNIGE Faculty of Medicine’s Department of Medicine and Translational Research Centre in Onco-Haematology (CRTOH). ‘‘This is why glioblastoma, unlike melanoma or certain lung cancers, for example, does not respond to standard immunotherapies. Our approach is therefore to provide the patient with the missing T cells by generating them in the laboratory.”
 
access your free copy
 
This report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.
Inside the report:
This report unlocks perspectives that show how automation is changing the scale and quality of discovery. The result is faster insight, stronger data and better science – access your free copy today
 
CAR-T cell therapy, widely used in some blood cancers, involves collecting a patient’s T cells, genetically modifying them to recognise tumour-specific markers, and re-injecting them. Yet identifying safe and effective targets in the highly heterogeneous environment of glioblastoma has been a major challenge for scientists.
A real-time imaging experiment (images taken at 0, 5 and 10 minutes) shows a CAR-T cell in contact with a glioblastoma cell (artificially marked in green). Credit: © Denis Migliorini
Professor Denis Migliorini, also of UNIGE and head of the neuro-oncology unit at HUG, describes earlier research identifying an important glioblastoma-related marker: PTPRZ1. 
“In a previous study, we identified an important target, the PTPRZ1 marker, which is present on the surface of certain tumour cells. However, attacking glioblastoma on a single target is not enough to avoid the risk of relapse.”
In a previous study, we identified an important target, the PTPRZ1 marker, which is present on the surface of certain tumour cells.
The team has now added a second, complementary target: Tenascin-C (TNC). This protein forms part of the extracellular matrix – the ‘jelly’ surrounding tumour cells. By engineering CAR-T cells to attack Tenascin-C, the researchers triggered inflammatory reactions that kill the cells producing it.
‘‘Furthermore, we have been able to demonstrate that CAR-T cells are capable of locally destroying cancer cells that do not produce Tenascin-C, which amplifies their activity without any risk of deleterious effects on healthy cells,” said Migliorini. 
A major barrier in CAR-T therapies is the rapid exhaustion of the engineered cells, which limits their impact. ‘‘By identifying three markers of cell exhaustion and counteracting their activity, we were able to significantly prolong the efficacy of CAR-T cells in mice with glioblastoma used as models of the human disease,” said Valérie Dutoit.
With strong pre-clinical results, the researchers are preparing to move into clinical trials, with the goal to generate genetically modified immune cells against several targets at once. The hope is that this will be able to reach as many cancer cells as possible. The trial, expected to begin within a year in Geneva and Lausanne, will tailor CAR-T cells to each patient to eradicate as many cells as possible, even when facing tumour heterogeneity.
Related topics
Cell Therapy, Central Nervous System (CNS), Chimeric Antigen Receptors (CARs), Clinical Trials, Drug Discovery Processes, Immuno-oncology, Oncology, T cells, Translational Science
Related conditions
Glioblastoma
Related organisations
the Geneva University Hospital, the University of Geneva
Related people
Professor Denis Migliorini (head of the neuro-oncology unit at HUG), Valérie Dutoit (the UNIGE Faculty of Medicine’s Department of Medicine and Translational Research Centre in Onco-Haematology)
By Drug Target Review
20 November 2025
No comments yet
Cell Therapy, Central Nervous System (CNS), Chimeric Antigen Receptors (CARs), Clinical Trials, Drug Discovery Processes, Immuno-oncology, Oncology, T cells, Translational Science
Glioblastoma
the Geneva University Hospital, the University of Geneva
Professor Denis Migliorini (head of the neuro-oncology unit at HUG), Valérie Dutoit (the UNIGE Faculty of Medicine’s Department of Medicine and Translational Research Centre in Onco-Haematology)
All subscriptions include online membership, giving you access to the journal and exclusive content.
By WuXi Biologics
By Michelle Lynskey (Vice President of Client Services – ICON Central Laboratories)
By Drug Target Review
By Drug Target Review
By Drug Target Review
Your email address will not be published. Required fields are marked *
Comment *
Name *
Email *
Website

Write for us | Advertise with us
T: +44 (0)1959 563311
F: +44 (0)1959 563123

Drug Target Review is published by:
Russell Publishing Ltd.
Court Lodge
Hogtrough Hill
Brasted, Kent, TN16 1NU
United Kingdom
© Russell Publishing Limited, 2010-2025. All rights reserved. Terms & Conditions | Privacy Policy | Cookie Policy
Website development by e-Motive Media Limited.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as “Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies enable the core functionality of the website, including security, network management and accessibility. These cookies do not store any personal information. You may disable these by changing your browser settings, but this may affect how the website functions.

Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.

Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.

Performance cookies include cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.

source